Abstract
Objective The aim of this article is to evaluate and compare two natural health product databases for the purpose of integrating them into a pharmacy information system in Canada. Methods This is a descriptive pilot study that compared the Natural Medicine Comprehensive Database® (NMCD) and Natural Standard® Database (NSD). We randomly chose five hospital patient files. For each drug prescription, we searched for and counted the number of potential natural health product–drug interactions in each database. Main outcome measure We compared all of the potential interactions between dexamethasone and the natural health products in both databases. We also evaluated the quality of a selection of references for 30 potential natural health product–dexamethasone interactions. Results Five pediatric patient files were selected for a total of 21 different common names. The number of potential natural health product–drug interactions identified varied from 12 (salbutamol-albuterol) to 129 (dexamethasone) in the NSD for an average of 63 ± 33. The number of potential natural health product–drug interactions identified varied from 1 (salbutamol-albuterol) to 96 (dexamethasone) in the NMCD for an average of 55 ± 27. There was no significant difference between the average number of potential natural health product–drug interactions between the databases (P = 0.40). The average number of common potential interactions was 9 ± 8. Thirty potential interactions of dexamethasone were compared. The number of abstracts per pair of interactions varied from 0 (Aloe-dexamethasone in the NSD) to 17 (dexamethasone-St. John’s wort in the NMCD). For the 10 pairs that were common to both databases, the number of abstracts given was 4.5 ± 4.7 for the NMCD and 3.1 ± 2.1 for the NSD (P = 0.41) and the average evaluation score was 4.6 ± 1.5 for the NMCD and 5.6 ± 1.2 for the NSD (P = 0.43). Conclusion This pilot study presents a comparison of potential natural health product–drug interactions from two different databases using two different scenarios in a hospital setting. The study reveals a high and variable number of pairs of natural health product–drug interactions per drug between the NSD and the NMCD. Further studies are necessary to evaluate the pertinence and hierarchy of the information offered by suppliers and natural health product databases.
Similar content being viewed by others
References
Health Canada. Natural Health Products Regulations. [cited on 3 Apr 2009]. http://www.hc-sc.gc.ca/dhp-mps/prodnatur/index-eng.php (visited on 5 May 2009).
Nestmann ER, Harwood M, Martyres S. An innovative model for regulating supplement products: natural health products in Canada. Toxicology. 2006;221:50–8.
Ohama H. Legal situation of supplements in the United States and European union. Yakugaku Zasshi. 2008;128:839–50.
Murty MP. ostmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives. Can J Physiol Pharmacol. 2007;85:952–5.
Laeeque H, Boon H, Kachan N, Cohen JC, D’Cruz J. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors. BMC Health Serv Res. 2006;6:63.
Health Canada. Baseline Natural Health Products Survey among consumers—March 2005. [cited on 13 Sept 2005]. http://www.hc-sc.gc.ca/dhp-mps/pubs/natur/eng_cons_survey-eng.php (visited on 5 May 2009).
Kelly JF, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med. 2005;165:281–6.
Ansani NT, Ciliberto NC, Freedy T. Hospital policies regarding herbal medicines. Am J Health-Syst Pharm. 2003;60:367–70.
Brubaker ML. Setting up the herbal formulary system for an alternative medicine clinic. Am J Health-Syst Pharm. 1998;55:435–6.
Cook TF, Frighetto L, Marra CA, Jewesson PJ. Patterns of use and patients’ attitudes toward complementary medications: a survey of adult general medicine patients at a major Canadian teaching hospital. Can J Clin Pharmacol. 2002;9:183–9.
Bazzie KL, Witmer DR, Pinto B, Bush C, Clark J, Deffenbaugh J. National survey of dietary supplement policies in acute care facilities. Am J Health-Syst Pharm. 2006;63:65–70.
De Smet PA, Floor-Schreudering A, Bouvy ML, Wensing M. Clinical risk management of interactions between natural products and drugs. Curr Drug Metab. 2008;9:1055–62.
Skalli S, Zaid A, Soulaymani R. Drug interactions with herbal medicines. Ther Drug Monit. 2007;29:679–86.
Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb–drug interactions: a literature review. Drugs. 2005;65:1239–82.
Joshi R, Medhi B. Natural product and drugs interactions, its clinical implication in drug therapy management. Saudi Med J. 2008;29:333–9.
Bent SH. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23:854–9.
Busse JW, Heaton G, Wu P, Wilson KR, Mills EJ. Disclosure of natural product use to primary care physicians: a cross-sectional survey of naturopathic clinic attendees. Mayo Clin Proc. 2005;80:616–23.
Bailey DG, Dresser GK. Natural products and adverse drug interactions. CMAJ. 2004;170:1531–2.
Traynor K. Report urges scientific standards for alternative medicine. Am J Health-Syst Pharm. 2005;62:562–8.
Kroll DJ. ASHP statement on the use of dietary supplements. Am J Health-Syst Pharm. 2004;61:1707–11.
Goldman RD, Rogovik AL, Lai D, Vohra S. Potential interactions of drug–natural health products and natural health products–natural health products among children. J Pediatr. 2008;152:521–6. 526.
Singh SR, Levine MA. Potential interactions between pharmaceuticals and natural health products in Canada. J Clin Pharmacol. 2007;47:249–58.
Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb–drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab. 2008;9:1063–120.
Clauson KA, Polen HH, Peak AM, Marsh WA, DiScala SL. Clinical decision support tools: personal digital assistant versus online dietary supplement databases. Ann Pharmacother. 2008;42:1592–9.
Scott GN, Elmer GW. Update on natural product–drug interactions. Am J Health Syst Pharm. 2002;59:339–47.
Brulotte J, Vohra S. Epidemiology of NHP-drug interactions: identification and evaluation. Curr Drug Metab. 2008;9:1049–54.
Charrois TL, Hill RL, Vu D, Foster BC, Boon HS, Cramer K, et al. Community identification of natural health product–drug interactions. Ann Pharmacother. 2007;41:1124–9.
Lebel D, Faubert G, Bussières JF. Intégration d’une base de données de produits de santé naturels à un progiciel pharmacie en établissement de santé. J Pharm Clin. 2009;28(2):103–7.
Funding
None.
Conflicts of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Faubert, G., Lebel, D. & Bussières, JF. A pilot study to compare natural health product–drug interactions in two databases in Canada. Pharm World Sci 32, 179–186 (2010). https://doi.org/10.1007/s11096-010-9364-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-010-9364-2